- Home
- CPBI vs MGX Comparison
CPBI vs MGX Comparison
Compare CPBI & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPBI
- MGX
- Stock Information
- Founded
- CPBI 2023
- MGX 2018
- Country
- CPBI United States
- MGX United States
- Employees
- CPBI N/A
- MGX N/A
- Industry
- CPBI
- MGX
- Sector
- CPBI
- MGX
- Exchange
- CPBI Nasdaq
- MGX NYSE
- Market Cap
- CPBI 57.1M
- MGX 65.0M
- IPO Year
- CPBI N/A
- MGX 2024
- Fundamental
- Price
- CPBI $14.83
- MGX $1.51
- Analyst Decision
- CPBI
- MGX Strong Buy
- Analyst Count
- CPBI 0
- MGX 4
- Target Price
- CPBI N/A
- MGX $14.75
- AVG Volume (30 Days)
- CPBI 6.1K
- MGX 355.5K
- Earning Date
- CPBI 01-01-0001
- MGX 05-16-2025
- Dividend Yield
- CPBI N/A
- MGX N/A
- EPS Growth
- CPBI 29.70
- MGX N/A
- EPS
- CPBI 1.62
- MGX N/A
- Revenue
- CPBI $18,546,000.00
- MGX $52,295,000.00
- Revenue This Year
- CPBI N/A
- MGX N/A
- Revenue Next Year
- CPBI N/A
- MGX $6.95
- P/E Ratio
- CPBI $9.17
- MGX N/A
- Revenue Growth
- CPBI 13.73
- MGX 16.84
- 52 Week Low
- CPBI $9.96
- MGX $1.23
- 52 Week High
- CPBI $15.50
- MGX $8.18
- Technical
- Relative Strength Index (RSI)
- CPBI 52.99
- MGX 45.48
- Support Level
- CPBI $14.70
- MGX $1.40
- Resistance Level
- CPBI $14.77
- MGX $1.64
- Average True Range (ATR)
- CPBI 0.06
- MGX 0.14
- MACD
- CPBI 0.02
- MGX -0.00
- Stochastic Oscillator
- CPBI 67.39
- MGX 26.19
About CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists primarily of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in our primary market area, as well as commercial real estate loans.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.